Results 21 to 30 of about 5,286 (232)
Disseminated fungal infection in a patient receiving zanubrutinib
Clinical Case Reports, 2023 Key Clinical Message We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.
Madalyn Walsh +3 more
doaj +1 more source
PLoS ONE, 2017 Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton's tyrosine kinase and phosphoinositide 3-kinase δ offer ...
Anella Yahiaoui +9 more
doaj +1 more source
Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE? [PDF]
, 2020 Systemic lupus erythematosus (SLE) is an autoimmune disease with a complex pathogenesis, which presents a great variability in its presentation and can affect almost all organs and systems.
Fasano, Serena +3 more
core +1 more source
A covalent BTK ternary complex compatible with targeted protein degradation
Nature Communications, 2023 Bridging covalent ligand discovery with chimeric degrader design has emerged as a mechanism to target proteins that lack enzymatic activity or are intractable.
James Schiemer +8 more
doaj +1 more source
Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
Current Neurology and Neuroscience Reports, 2022 Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with a chronic and often progressive disease course. The current disease-modifying treatments (DMTs) limit disease progression primarily by dampening immune cell activity in the peripheral blood or hindering their migration from the periphery into the CNS.
Raphael Schneider, Jiwon Oh
openaire +2 more sources
Switching immune signals on and off
eLife, 2015 Bruton's tyrosine kinase, an enzyme that is important for B cell function, can be activated in a number of ways.
Nam Chu, Philip A Cole
doaj +1 more source
Haematologica, 2015 Chronic lymphocytic leukemia is a malignancy of mature auto-reactive B cells. Genetic and functional studies implicate B-cell receptor signaling as a pivotal pathway in its pathogenesis.
Adrian Wiestner
doaj +1 more source
A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase
Royal Society Open Science, 2021 Bruton's tyrosine kinase (BTK) plays a vital role in mature B-cell proliferation, development and function. Its inhibitors have gradually been applied for the treatment of many B-cell malignancies. However, because of treatment-associated drug resistance
Simei Qiu, Yunfeng Liu, Quhuan Li
doaj +1 more source
eJHaem, 2021 ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi +9 more
doaj +1 more source
Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors
American Journal of Clinical Dermatology, 2020 The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. The first-generation inhibitor ibrutinib works by covalent irreversible binding to BTK, a non-receptor tyrosine kinase of the TEC (transient erythroblastopenia of childhood) family ...
Sibaud, Vincent +5 more
openaire +2 more sources